Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TWST vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: TWST 3 – 3 VCYT Matrix Metrics: TWST 5 – 5 VCYT

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). TWST carries a Unified Composite Score of 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Technical & Structure Timing Caution: TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TWST vs VCYT
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.04
-5.88% 1D
Market Cap $7.4B
TTM Revenue $459M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.8 · SMA20: $137.31 · SMA50: $149.83
VCYT NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (TWST 3 – 3 VCYT)

Columns: Metric · TWST · VCYT
1. Valuation Multiples VCYT
Forward P/E N/M 15.3x
Trailing P/E N/M 15.8x
PEG Ratio N/M N/M
EV / Revenue 16.1x 3.1x
2. Growth & Scale TWST
Revenue Growth (YoY) +27.9% +15.1%
Earnings Growth (YoY) +0.0% +58.3%
TTM Revenue (USD) $459M $582M
Market Cap $7.4B $2.0B
3. Profitability & Quality VCYT
Gross Margin 52.4% 74.2%
Operating Margin -28.8% 15.0%
Net Profit Margin -28.3% 21.8%
Return on Equity (ROE) -19.1% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) -$107M EBITDA $162M
Cash Flow Margin -23.4% EBITDA Mgn 27.8%
Net Cash / Leverage $13.61 Book/Sh · -19.1% ROE $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 100.1% (19th %ile) 197.3% (47th %ile)
Put/Call OI Skew 1.04x (Balanced) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity 81.2% of Rev ($373M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TWST (5) vs VCYT (5)
Institutional Metric TWST VCYT Criterion Row Edge
Market Capitalization
Scale
$7.4B $2.0B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M 15.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
N/M 15.3x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+27.9% +15.1% Higher Growth TWST
Operating Margin (TTM)
Profitability
-28.8% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
-28.3% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
-19.1% 9.4% Higher ROE VCYT
52-Week Range Position
Momentum
42% ($23–$220) 5% ($22–$61) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
3.13β · 126% Vol 3.01β · 199% Vol Lower Realized Risk TWST
Unified Institutional Score
Composite Signal
51.7 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$459M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
52.4% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$107M EBITDA ($13.61 Book/Sh · -19.1% ROE) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TWST +23.45 pp
TWST: -20.87% · VCYT: -44.32%
3M Horizon TWST +31.45 pp
TWST: -9.53% · VCYT: -40.98%
6M Horizon TWST +153.11 pp
TWST: +110.97% · VCYT: -42.14%
1Y Horizon TWST +291.08 pp
TWST: +251.3% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TWST Revenue VCYT Revenue TWST Op. Margin VCYT Op. Margin Margin Leader
FY2018 $30M $90M -277.5% -24.2% VCYT
FY2019 $50M $120M -200.1% -12.6% VCYT
FY2020 $90M $120M -155.5% -30.1% VCYT
FY2021 $130M $220M -115.4% -37.3% VCYT
FY2022 $200M $300M -115.3% -13.9% VCYT
FY2023 $250M $360M -88.6% -23.8% VCYT
FY2024 $310M $450M -70.6% 3.6% VCYT
FY2025 $380M $520M -36.2% 11.2% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.1%
IV Percentile 19th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.4B market capitalization and -28.8% operating margin.
OpEx & R&D Reinvestment 81.2% of Rev ($373M)
90D Engineering Disclosures 0 Published · Spatial Genomics
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ TWST vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). TWST carries a Unified Composite Score of 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: TWST posts +27.9% YoY revenue growth and +0.0% YoY earnings growth on $459M TTM revenue (52.4% gross margin, -28.8% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), TWST cumulative revenue shifted +1166.7% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, TWST deploys 81.2% of Rev ($373M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

VCYT screens cheaper on headline valuation multiples. TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.1x EV/Revenue (-23.4% EBITDA margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TWST (-19.1% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, TWST carries 100.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.